Paper Details

  1. Home
  2. Paper Details

Low-Dose Intravenous Immunoglobulin Treatment for Long-Standing Complex Regional Pain Syndrome: A Randomized Trial.

Author: AmblerGareth, BislaJatinder, CarganilloRoy, FrankBernhard, GoebelAndreas, GuptaRima, KellyJoanna, McCabeCandy, MurphyCaroline, PadfieldNick, PhillipsCeri, SandersMark, SerpellMick, ShenkerNick, ShoukreyKarim, WyattLynne

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Low-dose immunoglobulin treatment for 6 weeks was not effective in relieving pain in patients with moderate to severe CRPS of 1 to 5 years' duration. The study was inadequately powered to detect subgroup effects.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Two small trials suggest that low-dose intravenous immunoglobulin (IVIg) may improve the symptoms of complex regional pain syndrome (CRPS), a rare posttraumatic pain condition. OBJECTIVE: To confirm the efficacy of low-dose IVIg compared with placebo in reducing pain during a 6-week per...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.7326/M17-0509

データ提供：米国国立医学図書館（NLM）

Low-Dose Intravenous Immunoglobulin for Complex Regional Pain Syndrome: A Randomized Trial

Complex regional pain syndrome (CRPS) is a debilitating chronic pain condition that can significantly impact an individual's quality of life. This randomized trial investigates the efficacy of low-dose intravenous immunoglobulin (IVIg) in reducing pain in patients with CRPS. The researchers compared the effects of low-dose IVIg to a placebo in patients who had CRPS for 1 to 5 years. The study aimed to determine whether low-dose IVIg could provide significant pain relief for individuals suffering from this challenging condition.

Low-Dose IVIg: Ineffective for Chronic CRPS Pain

This study found that low-dose IVIg treatment was not effective in reducing pain in patients with moderate to severe CRPS of 1 to 5 years' duration. The researchers did not observe a significant difference in pain intensity between the IVIg group and the placebo group.

CRPS Treatment: Finding Effective Solutions

This study highlights the need for continued research to develop effective treatments for CRPS. The lack of efficacy of low-dose IVIg in this trial underscores the complexity of this condition and the need for alternative treatment strategies.

Dr.Camel's Conclusion

This study demonstrates the importance of rigorous scientific investigation in evaluating potential treatments for complex medical conditions. The findings suggest that low-dose IVIg may not be an effective treatment for chronic CRPS, but this research can help guide future studies and the development of new and more effective treatment strategies. Remember, just as a camel adapts to the challenges of the desert, so too must researchers adapt their approaches to find solutions for complex medical conditions.

Date :
  1. Date Completed 2017-10-10
  2. Date Revised 2022-03-10
Further Info :

Pubmed ID

28973211

DOI: Digital Object Identifier

10.7326/M17-0509

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.